Incyte aims for $1 billion growth by 2029 with new drug launches

From Yahoo Finance: 2025-06-15 05:49:00

Incyte Corporation (NASDAQ:INCY) is highlighted as one of the 8 cheap beginner stocks to buy right now. The company aims for $1 billion growth by 2029 through new drug launches and strategic goals presented at the 46th Annual Global Healthcare Conference. Revenue from Jakafi is expected to be driven by demand factors in the future.

In Q1 2025, Jakafi saw a 24% year-over-year growth, with demand, net pricing, and reduced destocking contributing to this increase. Incyte Corporation (NASDAQ:INCY) plans to introduce four new products or indications in 2025 to diversify its portfolio and generate additional revenue by 2029, focusing on demand-driven growth.

As an American global pharmaceutical company, Incyte Corporation (NASDAQ:INCY) leads in developing treatments for various diseases, including cancer. While INCY shows investment potential, other AI stocks may offer greater upside and less downside risk. Investors seeking an undervalued AI stock can explore opportunities related to Trump-era tariffs and onshoring trends.

For more insights on potential investments, check out the best short-term AI stock and other top stock recommendations for 2025 and retirement planning. Disclosure: None.

Read more: Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches